Online GLP-1 Programs in New Hampshire

Insurance

Does New Hampshire Medicaid cover GLP-1s?

Effective January 1, 2026, New Hampshire Medicaid stopped covering GLP-1s prescribed solely for weight loss, naming Saxenda, Wegovy, Zepbound, and their generics (NH DHHS, 2025). The state projected the change would trim GLP-1 spending from about $49.5 million to $41 million a year. Coverage continues for type 2 diabetes and other medical indications like cardiovascular risk and sleep apnea. A 2026 bill (SB 455) would restore weight-loss coverage.

Online Access

Getting a GLP-1 online in New Hampshire

GLP-1s are not controlled substances, so New Hampshire allows them to be prescribed via telehealth. The prescriber must hold a New Hampshire license, since treating a New Hampshire patient by telehealth is considered practicing medicine in the state (Center for Connected Health Policy, 2026). Online programs can serve residents statewide.

Compounding

Compounded semaglutide & tirzepatide in New Hampshire

Routine compounding of semaglutide and tirzepatide ended after the FDA resolved the shortages in early 2025 (FDA, 2025). New Hampshire adds no special carve-out beyond the federal 503A/503B framework, so compounding is limited to documented, patient-specific clinical need.

Demand

Where GLP-1 demand is highest in New Hampshire

About 31% of New Hampshire adults have obesity and roughly 10% have diagnosed diabetes, both among the lower rates in the country (CDC BRFSS via America's Health Rankings, 2024). Demand centers on Manchester and Nashua in the south. With Medicaid having dropped weight-loss coverage at the start of 2026, most access now runs through cash-pay and telehealth.

Questions

New Hampshire GLP-1 FAQ

Compound Guides

The GLP-1s behind these programs

Sources

How we sourced this page

Coverage, prevalence, and policy figures are drawn from primary and authoritative sources, last reviewed June 2026.